C4X Discovery agrees licensing deal with Sanofi
Sanofi could pay up to €414m for C4X Discovery’s oral IL-17A inhibitor programme
Read More
Tag: IL-17
Lilly’s Taltz cleared to treat psoriatic arthritis
US regulators have expanded the scope of Eli Lilly’s plaque psoriasis drug Taltz to include the treatment patients with psoriatic arthritis.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
